UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 31, 2020

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact Name of Registrant as Specified in Its Charter)

(State o	Delaware or Other Jurisdiction of Incorporation)	001-35547 (Commission File Number)	36-4392754 (IRS Employer Identification No.)
		ndise Mart Plaza, Suite 2024, Chicago, Address of Principal Executive Offices) (Zip Coo	
	Registrant's Te	elephone Number, Including Area Code	e: (800) 334-8534
	(Former	Name or Former Address, if Changed Since La	st Report)
Check the ap		s intended to simultaneously satisfy the f	filing obligation of the registrant under any of the
	Written communications pursuant to Rule	425 under the Securities Act (17 CFR 23	30.425)
	Soliciting material pursuant to Rule 14a-1	2 under the Exchange Act (17 CFR 240.	14a-12)
	Pre-commencement communications purs	suant to Rule 14d-2(b) under the Exchang	ge Act (17 CFR 240.14d-2(b))
	Pre-commencement communications purs	suant to Rule 13e-4(c) under the Exchang	ge Act (17 CFR 240.13e-4(c))
Securities re	gistered pursuant to Section 12(b) of the Act	· ·	
Commo	<u>Title of Each Class</u> n Stock, par value \$0.01 per share	Trading Symbol MDRX	Name of Each Exchange on which Registered The Nasdaq Stock Market LLC (Nasdaq Global Select Market)
	check mark whether the registrant is an emer Rule 12b-2 of the Securities Exchange Act of		405 of the Securities Act of 1933 (§230.405 of this
			Emerging growth company □
	ng growth company, indicate by check mark nancial accounting standards provided pursu		e extended transition period for complying with any new . \Box

Item 2.01 Completion of Acquisition or Disposition of Assets.

On December 31, 2020, Allscripts Healthcare, LLC, a North Carolina limited liability company ("Allscripts Healthcare") and subsidiary of Allscripts Healthcare Solutions, Inc., a Delaware corporation (the "Company"), completed the previously-announced divestiture of substantially all of the assets of Allscripts Healthcare's business commonly referred to as its CarePort Health business ("CarePort Business") to Carbonite Buyer, Inc., a Delaware corporation ("Carbonite"), pursuant to a Purchase Agreement dated October 12, 2020, for a purchase price of \$1.35 billion (the "CarePort Divestiture"). The CarePort Divestiture was structured as a sale of assets primarily related to the CarePort Business (and the transfer of certain liabilities in connection therewith) by Allscripts Healthcare to Carbonite.

The CarePort Purchase Agreement was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by the Company on October 15, 2020 and is incorporated herein by reference.

Item 3.02 Unregistered Sales of Equity Securities.

The Company completed the issuance of a warrant to a commercial partner on December 31, 2020, as part of a new and expanded commercial relationship, pursuant to which the warrant holder has the right to purchase 1.5 million shares of the Company's common stock at an exercise price of \$9.82 per share (the closing price of the Company's common stock on the date definitive agreements with respect to the new and expanded commercial relationship were executed), subject to customary anti-dilution adjustments. The warrant vests in four equal annual installments of 375,000 shares beginning on December 31, 2020 with each additional installment vesting annually thereafter. The warrant expires on December 31, 2026 and becomes void if certain specified changes to the parties' commercial relationship occur. The warrant was issued and sold in reliance upon an exemption from registration under the Securities Act of 1933, as amended (the "Securities Act"), afforded by Section 4(a)(2) of the Securities Act and rules promulgated thereunder and corresponding provisions of state securities laws. The commercial partner is an "accredited investor" as defined in Rule 501(a) under the Securities Act.

Item 7.01 Regulation FD Disclosure.

On January 4, 2021, the Company issued a press release announcing the completion of the CarePort Divestiture. A copy of the Company's press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(b) Pro Forma Financial Information

The unaudited pro forma consolidated financial information of the Company giving effect to the CarePort Divestiture is filed as Exhibit 99.2 hereto and is incorporated herein by reference.

(d) Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 4, 2021

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

By: /s/ Eric Jacobson

Eric Jacobson

Senior Vice President and Corporate Secretary



Allscripts closes previously announced sale of CarePort Health business

CHICAGO – January 4, 2021 – On December 31, 2020, Allscripts (NASDAQ: MDRX) closed the previously announced sale of its CarePort Health business to WellSky® Corporation for \$1.35 billion. CarePort solutions assist hundreds of hospitals and thousands of post-acute care providers to efficiently coordinate and transition patients through different settings of care.

About Allscripts

Allscripts (NASDAQ: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers and consumers to make better decisions, delivering better care for healthier populations. To learn more, visit www.allscripts.com, Twitter, YouTube and The Allscripts Blog.

###

© 2021 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

For more information contact:

Investors:
Stephen Shulstein
312-386-6735
Stephen.Shulstein@allscripts.com

Media:
Concetta Rasiarmos
312-447-2466
concetta.rasiarmos@allscripts.com

Allscripts Healthcare Solutions, Inc. Summary of Unaudited Pro Forma Financial Information

(Dollars in thousands, except per share amounts)

Overview

On December 31, 2020, Allscripts Healthcare, LLC, a North Carolina limited liability company ("Allscripts Healthcare") and subsidiary of Allscripts Healthcare Solutions, Inc., a Delaware corporation (the "Company"), completed the previously-announced divestiture of substantially all of the assets of Allscripts Healthcare's business commonly referred to as its CarePort Health business ("CarePort Business") to Carbonite Buyer, Inc., a Delaware corporation ("Carbonite"), pursuant to a Purchase Agreement dated October 12, 2020, for a purchase price of \$1.35 billion (the "CarePort Divestiture"). The CarePort Divestiture was structured as a sale of assets primarily related to the CarePort Business (and the transfer of certain liabilities in connection therewith) by Allscripts Healthcare to Carbonite.

Basis of Presentation

The unaudited pro forma consolidated balance sheet as of September 30, 2020 provides the financial position of the Company giving effect to the disposition of the CarePort Business. The unaudited pro forma consolidated statements of operations for the nine months ended September 30, 2020 and the years ended December 31, 2019, 2018 and 2017 have been prepared to show the operating results of the Company giving effect to the disposition of the CarePort Business as if the transaction had occurred on January 1, 2017.

The unaudited financial information for the Company was derived from, and should be read in conjunction with, the Company's unaudited interim consolidated financial statements included in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on October 30, 2020 and the audited consolidated financial statements for the years ended December 31, 2019, 2018 and 2017 included in the Company's Annual Report on Form 10-K filed with the SEC on March 2, 2020.

The pro forma adjustments are described in the notes to the unaudited pro forma financial information. The unaudited pro forma financial information included herein is for informational purposes only and is not necessarily indicative of what the Company's financial performance and financial position would have been without the consolidation of the CarePort Business for the periods presented. Actual results may differ significantly from those reflected here in the unaudited pro forma consolidated financial statements for various reasons, including but not limited to, the differences between the assumptions used to prepare the unaudited pro forma condensed consolidated financial statements and actual results had the transaction actually occurred on January 1, 2017.

Financial Tables Follow

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET AS OF SEPTEMBER 30, 2020

(In thousands, except per share amounts)	Allscripts Historical (A)		of CarePort		Pro Forma		
ASSETS						_	
Current assets:							
Cash and cash equivalents	\$ 218,701	\$	404,862	(C)	\$	623,563	
Restricted cash	6,209		0			6,209	
Accounts receivable, net of allowance of \$37,025 as of September 30, 2020	381,888		(20,636)	(D)		361,252	
Contract assets, net of allowance of \$1,068 as of September 30, 2020	101,333		(1,148)			100,185	
Prepaid expenses and other current assets	135,869		(2,142)			133,727	
Assets held for sale	104,782		0			104,782	
Total current assets	 948,782		380,936			1,329,718	
Fixed assets, net	70,027		(61)			69,966	
Software development costs, net	241,656		(10,977)			230,679	
Intangible assets, net	329,011		(5,915)			323,096	
Goodwill	1,287,197		(313,243)			973,954	
Deferred taxes, net	5,881		(321)			5,560	
Contract assets - long-term, net of allowance of \$4,273 as of September 30, 2020	42,805		(765)			42,040	
Right-of-use assets - operating leases	102,217		(822)			101,395	
Other assets	118,689		(1,196)			117,493	
Total assets	\$ 3,146,265	\$	47,636		\$	3,193,901	

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET (CONTINUED) AS OF SEPTEMBER 30, 2020

(In thousands, except per share amounts)	Allscripts istorical (A)	Sale	of CarePort		Pro Forma
LIABILITIES AND STOCKHOLDERS' EQUITY	`				
Current liabilities:					
Accounts payable	\$ 53,627	\$	327,954	(E)	\$ 381,581
Accrued expenses	166,180		(381)		165,799
Accrued compensation and benefits	97,515		(1,349)		96,166
Deferred revenue	339,239		(28,539)		310,700
Current maturities of long-term debt	48,293		(48,293)	(F)	0
Current operating lease liabilities	22,317		(320)		21,997
Liabilities related to assets held for sale	17,479		0		17,479
Total current liabilities	744,650		249,072		993,722
Long-term debt	1,026,048		(816,707)	(F)	209,341
Deferred revenue	11,570		(943)		10,627
Deferred taxes, net	24,534		(4,498)		20,036
Long-term operating lease liabilities	98,866		(552)		98,314
Other liabilities	32,210		0		32,210
Total liabilities	1,937,878		(573,628)		1,364,250
Commitments and contingencies					
Stockholders' equity:					
Preferred stock: \$0.01 par value, 1,000 shares authorized, no shares issued and					
outstanding as of September 30, 2020	0		0		0
Common stock: \$0.01 par value, 349,000 shares authorized as of September 30, 2020; 274,471 and 157,978 shares issued and outstanding as of September 30, 2020,					
respectively	2,744		0		2,744
Treasury stock: at cost, 116,493 shares as of September 30, 2020	(625,246)		0		(625,246)
Additional paid-in capital	1,929,396		0		1,929,396
Accumulated deficit	(94,706)		621,264	(G)	526,558
Accumulated other comprehensive loss	(3,801)		0		(3,801)
Total stockholders' equity	1,208,387		621,264		1,829,651
Total liabilities and stockholders' equity	\$ 3,146,265	\$	47,636		\$ 3,193,901

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2020

(In thousands, except per share amounts)		ripts Historical (A)	CareP	ort Historical]	Pro Forma	
Revenue:			<u> </u>				
Software delivery, support and maintenance	\$	770,180	\$	(71,168)		\$	699,012
Client services		454,786		(4,146)			450,640
Total revenue		1,224,966		(75,314)		·	1,149,652
Cost of revenue:							_
Software delivery, support and maintenance		225,879		(5,253)			220,626
Client services		420,185		(5,576)			414,609
Amortization of software development and acquisition-related assets		95,860		(3,257)			92,603
Total cost of revenue		741,924		(14,086)			727,838
Gross profit		483,042		(61,228)			421,814
Selling, general and administrative expenses		309,139		(8,214)			300,925
Research and development		158,913		(3,819)			155,094
Asset impairment charges		210		0			210
Amortization of intangible and acquisition-related assets		19,347		0			19,347
Loss from operations		(4,567)		(49,195)			(53,762)
Interest expense		(31,280)		13,149	(H)		(18,131)
Other income, net		45		0			45
Impairment of long-term investments		(1,575)		0			(1,575)
Equity in net income of unconsolidated investments		17,417		0			17,417
Loss before income taxes		(19,960)		(36,046)			(56,006)
Income tax provision		(7,457)		9,372			1,915
Net loss		(27,417)		(26,674)			(54,091)
Net loss attributable to non-controlling interests		0		0			0
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	\$	(27,417)	\$	(26,674)		\$	(54,091)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share - Basic	\$	(0.17)	\$	(0.16)		\$	(0.33)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share - Diluted	\$	(0.17)	\$	(0.16)		\$	(0.33)
Designation of the state of the		162,002					1/2 002
Basic weighted average shares outstanding		162,092					162,092
Diluted weighted average shares outstanding		162,092					162,092

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2019

(In thousands, except per share amounts)		ripts Historical (B)	CareP	ort Historical		Pro Forma		
Revenue:								
Software delivery, support and maintenance	\$	1,126,486	\$	(85,819)	\$	1,040,667		
Client services		645,191		(6,887)		638,304		
Total revenue		1,771,677		(92,706)		1,678,971		
Cost of revenue:								
Software delivery, support and maintenance		358,946		(7,909)		351,037		
Client services		583,111		(4,998)		578,113		
Amortization of software development and acquisition-related assets		116,040		(2,861)		113,179		
Total cost of revenue	<u> </u>	1,058,097		(15,768)	<u> </u>	1,042,329		
Gross profit		713,580		(76,938)		636,642		
Selling, general and administrative expenses		419,774		(12,607)		407,167		
Research and development		254,509		(4,879)		249,630		
Asset impairment charges		10,837		0		10,837		
Goodwill impairment charge		25,700		0		25,700		
Amortization of intangible and acquisition-related assets		27,216		0		27,216		
Loss from operations		(24,456)		(59,452)		(83,908)		
Interest expense		(43,172)		20,699 (H)		(22,473)		
Other loss, net		(138,902)		0		(138,902)		
Impairment of long-term investments		(651)		0		(651)		
Equity in net income of unconsolidated investments		665		0		665		
Loss before income taxes	<u> </u>	(206,516)		(38,753)	<u> </u>	(245,269)		
Income tax benefit		23,914		10,076		33,990		
Net loss		(182,602)		(28,677)		(211,279)		
Net loss attributable to non-controlling interests		424		0		424		
Net loss attributable to Allscripts Healthcare Solutions, Inc.								
stockholders	\$	(182,178)	\$	(28,677)	\$	(210,855)		
Net loss attributable to Allscripts Healthcare								
Solutions, Inc. stockholders per share - Basic	\$	(1.10)	\$	(0.17)	\$	(1.27)		
Net loss attributable to Allscripts Healthcare	-							
Solutions, Inc. stockholders per share - Diluted	\$	(1.10)	\$	(0.17)	\$	(1.27)		
1	<u>-</u>		<u> </u>		<u>-</u>			
Basic weighted average shares outstanding		166,306				166,306		
Diluted weighted average shares outstanding		166,306				166,306		

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2018

(In thousands, except per share amounts)	Allscri	ots Historical (B)	Carel	Port Historical	Pro Forma
Revenue:					
Software delivery, support and maintenance	\$	1,128,263	\$	(82,099)	\$ 1,046,164
Client services		621,699		(7,167)	614,532
Total revenue		1,749,962		(89,266)	1,660,696
Cost of revenue:		_		_	
Software delivery, support and maintenance		357,039		(6,492)	350,547
Client services		565,504		(4,828)	560,676
Amortization of software development and acquisition-related assets		102,876		(3,440)	99,436
Total cost of revenue		1,025,419		(14,760)	1,010,659
Gross profit		724,543		(74,506)	650,037
Selling, general and administrative expenses		450,967		(11,924)	439,043
Research and development		268,409		(4,446)	263,963
Asset impairment charges		58,166		0	58,166
Goodwill impairment charge		13,466		0	13,466
Amortization of intangible and acquisition-related assets		26,587		0	26,587
Loss from operations		(93,052)		(58,136)	(151,188)
Interest expense		(50,914)		0	(50,914)
Other income, net		74		0	74
Gain on sale of businesses, net		172,258		0	172,258
Impairment of long-term investments		(15,487)		0	(15,487)
Equity in net income of unconsolidated investments		259		0	259
Income from continuing operations before income taxes		13,138		(58,136)	(44,998)
Income tax provision		(469)		15,115	14,646
Income from continuing operations, net of tax		12,669		(43,021)	(30,352)
Loss from discontinued operations		(72,836)		0	(72,836)
Gain on sale of Netsmart		500,471		0	500,471
Income tax effect on discontinued operations		(32,497)		0	(32,497)
Income from discontinued operations, net of tax		395,138		0	395,138
Net income		407,807		(43,021)	364,786
Net loss attributable to non-controlling interests		4,527		0	4,527
Accretion of redemption preference on redeemable convertible					
non-controlling interest - discontinued operations		(48,594)		0	(48,594)
Net income attributable to Allscripts Healthcare					
Solutions, Inc. stockholders	\$	363,740	\$	(43,021)	\$ 320,719
Net income attributable to Allscripts Healthcare					
Solutions, Inc. stockholders per share:					
Basic					
Continuing operations	\$	0.10	\$	(0.25)	\$ (0.15)
Discontinued operations		1.97		0.00	1.97
Net income attributable to Allscripts Healthcare				-	
Solutions, Inc. stockholders per share	\$	2.07	\$	(0.25)	\$ 1.82

Diluted			
Continuing operations	\$ 0.10	\$ (0.20)	\$ (0.10)
Discontinued operations	1.94	0.00	1.94
Net loss attributable to Allscripts Healthcare		 _	
Solutions, Inc. stockholders per share	\$ 2.04	\$ (0.20)	\$ 1.84
Basic weighted average shares outstanding	176,038		176,038
Diluted weighted average shares outstanding	178,529		178,529

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS FOR THE YEAR ENDED DECEMBER 31, 2017

Revenue	(In thousands, except per share amounts)	Allscri	pts Historical (B)	Care	Port Historical	 Pro Forma
Sample S						
Total revenue	Software delivery, support and maintenance	\$	958,187	\$	(84,694)	\$ 873,493
Cost of revenue: 295,593 (6,012) 289,581 Software delivery, support and maintenance 295,593 (6,012) 289,581 Client services 484,591 (4,765) 479,826 Amortization of software development and acquisition-related assets 864,909 (14,309) 850,000 Gross profit 652,799 (78,795) 554,004 Selling, general and administrative expenses 400,688 (5,940) 394,748 Selling, general and administrative expenses 400,688 (5,940) 394,748 Research and development 202,282 (3,055) 199,227 Amortization of intangible and acquisition-related assets 17,345 0 17,345 Income from operations 12,484 (69,800) (57,316) Interest expense (37,540) 0 (615,290) Other income, net (512) 0 (512) Unpairment of and losses on long-term investments 821 0 821 Loss from continuing operations before income taxes (190,337) (69,800) (259,837) Income	Client services		539,521		(8,410)	 531,111
Software delivery, support and maintenance 295,931 (6,012) 289,581 Client services 484,591 (4,765) 479,826 Amortization of software development and acquisition-related assets 844,295 (3,532) 81,193 Total cost of revenue 864,909 (14,309) 850,000 Gross profit 632,799 (78,795) 554,004 Selling, general and administrative expenses 400,688 (5,940) 394,748 Research and development 202,282 (3,055) 199,227 Amortization of intangible and acquisition-related assets 17,345 0 173,455 Income from operations 12,484 (69,800) (57,316) Interest expense (37,540) 0 (37,540) Other income, net (512) 0 (612,290) Equity in net income of unconsolidated investments 821 0 821 Loss from continuing operations before income taxes (190,037) (69,800) (259,837) Income tax benefit 5,514 18,148 23,662 Loss from continuing operat	Total revenue		1,497,708		(93,104)	1,404,604
Client services	Cost of revenue:					
Amortization of software development and acquisition-related assets 84,725 (3,532) 81,193 Total cost of revenue 864,909 (14,309) 820,600 Gross profit 632,799 (78,795) 554,006 Selling, general and administrative expenses 400,888 (5,940) 394,748 Research and development 202,282 (3,055) 199,227 Amortization of intangible and acquisition-related assets 17,345 0 17,345 Income from operations 12,484 (69,800) (57,516) Interest expense (37,540) 0 (512) Other income, net (512) 0 (512) Income from operations before income tax (162,90) 0 (165,200) Equity in net income of unconsolidated investments 821 0 821 Loss from continuing operations before income taxes (190,037) (69,800) 225,837 Income tax effect on discontinued operations (184,523) (51,652) 236,175 Loss from continuing operations, net of tax (184,523) 0 42,263	Software delivery, support and maintenance		295,593		(6,012)	289,581
Total cost of revenue 864,909 (14,309) 850,600 Gross profit 632,799 (78,795) 554,004 Selling, general and administrative expenses 400,688 (5,940) 394,748 Research and development 202,282 (3,055) 199,227 Amorization of intangible and acquisition-related assets 17,345 0 17,345 Income from operations (37,540) 0 (37,540) Increst expense (37,540) 0 (37,540) Other income, net (512) 0 (162,200) Impairment of and losses on long-term investments (152) 0 (162,200) Equity in net income of unconsolidated investments 821 0 821 Loss from continuing operations before income taxes (190,37) (69,800) 259,837 Income tax benefit 5,514 18,148 23,662 Loss from continuing operations, net of tax (184,523) (51,652) (236,175) Income tax effect on discontinued operations (19,45) (5,54) (30,824) Net loss	Client services		484,591		(4,765)	479,826
Cross profit Cros	Amortization of software development and acquisition-related assets		84,725		(3,532)	81,193
Selling, general and administrative expenses 400,688 (5,940) 394,748 Research and development 202,282 (3,055) 199,227 Amortization of intangible and acquisition-related assets 17,345 0 17,345 Income from operations 12,484 (69,800) (57,316) Interest expense (37,540) 0 (512,500) Other income, not (165,290) 0 (165,290) Equity in net income of unconsolidated investments (165,290) 0 (259,837) Income training operations before income taxes (190,037) (69,800) (259,837) Income tax benefit 5,514 18,148 23,662 Loss from continuing operations, net of tax (188,223) (51,652) (236,175) Loss from discontinued operations (184,523) (51,652) (236,175) Income tax effect on discontinued operations (184,523) (51,652) (205,837) Income tax effect on discontinued operations at of tax 30,348 0 30,348 Net loss (154,175) (51,652) (205,837)	Total cost of revenue		864,909		(14,309)	850,600
Research and development 202,282 (3,055) 199,227 Amortization of intangible and acquisition-related assets 17,345 0 17,345 Income from operations 12,484 (69,800) (57,316) Interest expense (37,540) 0 (37,540) Other income, net (512) 0 (512) Impairment of and losses on long-term investments (165,290) 0 (165,290) Equity in net income of unconsolidated investments 821 0 821 Loss from continuing operations before income taxes (190,037) (69,800) (259,837) Income tax benefit 5,514 18,148 23,662 Loss from continuing operations, net of tax (184,523) (51,652) (236,175) Loss from discontinued operations (11,915) 0 (11,915) Income tax effect on discontinued operations (154,175) (51,652) (205,827) Net loss (154,175) (51,652) (205,827) Net loss attributable to non-controlling interests (1,566) 0 1,566 Accret	Gross profit		632,799		(78,795)	554,004
Amortization of intangible and acquisition-related assets 17,345 0 17,345 Income from operations 12,484 (69,800) (57,316) Interest expense (37,540) 0 (37,540) Other income, net (512) 0 (512) Impairment of and losses on long-term investments (165,290) 0 (165,290) Equity in net income of unconsolidated investments 821 0 821 Loss from continuing operations before income taxes (190,037) (69,800) (259,837) Income tax benefit 5,514 18,148 23,662 Loss from continuing operations, net of tax (184,523) (51,652) (236,175) Loss from discontinued operations (1,915) 0 (11,915) Income from discontinued operations, net of tax 30,348 0 30,348 Net loss (154,175) (51,652) (205,827) Net loss attributable to non-controlling interests 1,566 0 1,566 Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations 43,850 (5	Selling, general and administrative expenses		400,688		(5,940)	394,748
Income from operations	Research and development		202,282		(3,055)	199,227
Interest expense (37,540) (0 (37,540) (0 (37,540) (0 (512) (0 (Amortization of intangible and acquisition-related assets		17,345		0	17,345
Interest expense (37,540) (0 (37,540) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (0 (512) (5162) (0 (512) (5162) (5162) (5162) (5162) (51632) (5	Income from operations		12,484		(69,800)	(57,316)
Other income, net (512) 0 (512) Impairment of and losses on long-term investments (165,290) 0 (165,290) Equity in net income of unconsolidated investments 821 0 821 Loss from continuing operations before income taxes (190,037) (69,800) (259,837) Income tax benefit 5,514 18,148 23,662 Loss from continuing operations, net of tax (184,523) (51,652) (236,175) Loss from discontinued operations (11,915) 0 (11,915) Income tax effect on discontinued operations 42,263 0 42,263 Income from discontinued operations, net of tax 30,348 0 30,348 Net loss (154,175) (51,652) (205,827) Net loss (154,175) (51,652) (205,827) Net loss attributable to non-controlling interests 1,566 0 1,566 Accretion of redemption preference on redeemable convertible (43,850) 0 (43,850) Net income attributable to Allscripts Healthcare (196,459) (51,652) (248,111)	•					
Equity in net income of unconsolidated investments 821 0 821 Loss from continuing operations before income taxes (190,037) (69,800) (259,837) Income tax benefit 5,514 18,148 23,662 Loss from continuing operations, net of tax (184,523) (51,652) (236,175) Loss from discontinued operations (119,15) 0 (11,915) Income tax effect on discontinued operations 42,263 0 42,263 Income from discontinued operations, net of tax 30,348 0 30,348 Net loss attributable to non-controlling interests (154,175) (51,652) (205,827) Net loss attributable to non-controlling interests (154,175) (165,20) (205,827) Net income attributable to Allscripts Healthcare (43,850) 0 (43,850) Net income attributable to Allscripts Healthcare (196,459) (51,652) (248,111) Net loss attributable to Allscripts Healthcare (196,459) (10,28) (10,28) Solutions, Inc. stockholders per share: (10,29) (10,28) (10,28) Net loss attributable to Allscripts Healthcare (10,29) (10,29) (10,29) Net loss attributable to Allscripts Healthcare (10,29) (10,29) (10,29) Net loss attributable to Allscripts Healthcare (10,29) (10,29) (10,29) (10,29) Net loss attributable to Allscripts Healthcare (10,29) (10,2	•				0	
Loss from continuing operations before income taxes	Impairment of and losses on long-term investments		(165,290)		0	(165,290)
Income tax benefit			821		0	821
Income tax benefit	Loss from continuing operations before income taxes		(190,037)		(69,800)	(259,837)
Loss from discontinued operations (11,915) 0 (11,915) Income tax effect on discontinued operations 42,263 0 42,263 Income from discontinued operations, net of tax 30,348 0 30,348 Net loss (154,175) (51,652) (205,827) Net loss attributable to non-controlling interests 1,566 0 1,566 Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations (43,850) 0 (43,850) Net income attributable to Allscripts Healthcare Solutions, Inc. stockholders (196,459) (51,652) (248,111) Net loss attributable to Allscripts Healthcare (196,459) (10,28) (10,28) Solutions, Inc. stockholders per share: (10,29) (10,28) (10,28) Discontinued operations (10,29) (10,28) (10,28) Diluted (10,29) (10,28) (10,28) (10,28) (10,28) Continuing operations (10,29) (10,28) (1	Income tax benefit		5,514		18,148	23,662
Loss from discontinued operations (11,915) 0 (11,915) Income tax effect on discontinued operations 42,263 0 42,263 Income from discontinued operations, net of tax 30,348 0 30,348 Net loss (154,175) (51,652) (205,827) Net loss attributable to non-controlling interests 1,566 0 1,566 Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations (43,850) 0 (43,850) Net income attributable to Allscripts Healthcare Solutions, Inc. stockholders (196,459) (51,652) (248,111) Net loss attributable to Allscripts Healthcare (196,459) (10,28) (10,28) Solutions, Inc. stockholders per share: (10,29) (10,28) (10,28) Discontinued operations (10,29) (10,28) (10,28) Diluted (10,29) (10,28) (10,28) (10,28) (10,28) Continuing operations (10,29) (10,28) (1	Loss from continuing operations, net of tax		(184,523)		(51,652)	(236,175)
Income tax effect on discontinued operations						
Income from discontinued operations, net of tax 30,348 0 30,348 Net loss (154,175) (51,652) (205,827) Net loss attributable to non-controlling interests 1,566 0 1,566 Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations (43,850) 0 (43,850) Net income attributable to Allscripts Healthcare Solutions, Inc. stockholders (196,459) (51,652) (248,111) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share: Solutions, Inc. stockholders per share: Solutions, Inc. stockholders per share: Solutions, Inc. stockholders per share (1,02) (0,28) (1,30) Net loss attributable to Allscripts Healthcare (0,07) (0,07) (0,07) Net loss attributable to Allscripts Healthcare (0,07) (0,08) (1,37) Solutions, Inc. stockholders per share (1,09) (0,28) (1,37) Diluted Continuing operations (1,02) (0,28) (1,30)					0	
Net loss attributable to non-controlling interests 1,566 0 1,566 Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations (43,850) 0 (43,850) Net income attributable to Allscripts Healthcare Solutions, Inc. stockholders (196,459) (51,652) (248,111) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share: Basic Continuing operations (1,02) (0,28) (1,30) Net loss attributable to Allscripts Healthcare (1,00) (1,30) Discontinued operations (1,09) (0,28) (1,37) Diluted Continuing operations (1,02) (0,28) (1,30) Diluted Continuing operations (1,02) (0,28) (1,30) Continuing operations (1,02) (1,02) (1,30) Continuing operations (1,02) (1,02) (1,30) Continuing operations (1,02) (1,02) (1,02) Continuing operat	•			_	0	
Net loss attributable to non-controlling interests	•				(51.652)	
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations Net income attributable to Allscripts Healthcare Solutions, Inc. stockholders Solutions, Inc. stockholders Solutions, Inc. stockholders Solutions, Inc. stockholders Solutions, Inc. stockholders per share: Basic Continuing operations Solutions Solut					/	
Net income attributable to Allscripts Healthcare Solutions, Inc. stockholders Solutions, Inc. stockholders per share: Basic Continuing operations Solutions			, , , ,			,
Net income attributable to Allscripts Healthcare \$ (196,459) \$ (51,652) \$ (248,111)			(43,850)		0	(43,850)
Solutions, Inc. stockholders \$ (196,459) \$ (51,652) \$ (248,111)	•					
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share: Basic Continuing operations \$ (1.02) \$ (0.28) \$ (1.30) Discontinued operations (0.07) 0.00 (0.07) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share \$ (1.09) \$ (0.28) \$ (1.37) Diluted Continuing operations \$ (1.02) \$ (0.28) \$ (1.30)		\$	(196,459)	\$	(51,652)	\$ (248,111)
Solutions, Inc. stockholders per share: Basic			<u> </u>		•	
Basic Continuing operations \$ (1.02) \$ (0.28) \$ (1.30) Discontinued operations (0.07) 0.00 (0.07) Net loss attributable to Allscripts Healthcare \$ (1.09) \$ (0.28) \$ (1.37) Solutions, Inc. stockholders per share \$ (1.09) \$ (0.28) \$ (1.37) Diluted \$ (1.02) \$ (0.28) \$ (1.30)						
Discontinued operations (0.07) 0.00 (0.07) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share \$ (1.09) \$ (0.28) \$ (1.37) Diluted Continuing operations \$ (1.02) \$ (0.28) \$ (1.30)	•					
Discontinued operations (0.07) 0.00 (0.07) Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share \$\frac{1.09}{2}\$\$ \$\frac{1.09}{2}\$\$ \$\frac{0.28}{2}\$\$ \$\frac{1.37}{2}\$\$ Diluted Continuing operations \$\frac{1.02}{2}\$\$\$ \$\frac{0.28}{2}\$\$\$ \$\frac{1.30}{2}\$\$	Continuing operations	\$	(1.02)	\$	(0.28)	\$ (1.30)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share \$ (1.09) \$ (0.28) \$ (1.37) Diluted Continuing operations \$ (1.02) \$ (0.28) \$ (1.30)			(0.07)		0.00	(0.07)
Solutions, Inc. stockholders per share \$ (1.09) \$ (0.28) \$ (1.37) Diluted Continuing operations \$ (1.02) \$ (0.28) \$ (1.30)	•					, and the second
Continuing operations $$ (1.02) $ (0.28) $ (1.30)$		\$	(1.09)	\$	(0.28)	\$ (1.37)
Continuing operations $$ (1.02) $ (0.28) $ (1.30)$						
Continuing operations $$ (1.02) $ (0.28) $ (1.30)$	Diluted					
. .		\$	(1.02)	\$	(0.28)	\$ (1.30)
			(0.07)		0.00	(0.07)

Net loss attributable to Allscripts Healthcare				
Solutions, Inc. stockholders per share	\$ (1.09)	\$	(0.28)	\$ (1.37)
	 	-		
Basic weighted average shares outstanding	180,830			180,830
Diluted weighted average shares outstanding	180,830			180,830

The Company's Unaudited Pro Forma Consolidated Balance Sheets as of September 30, 2020, the Unaudited Pro Forma Consolidated Statement of Operations for the Nine Months Ended September 30, 2020 and the Years Ended December 31, 2019, 2018 and 2017 include the following:

- (A) As reported in the Quarterly Report on Form 10-Q filed by the Company with the SEC on October 30, 2020.
- (B) As reported in the Annual Report on Form 10-K filed by the Company with the SEC on March 2, 2020.
- (C) Represents proceeds received, net of transaction fees and expenses paid out at closing and debt repayment (see Tickmark F).
- (D) CarePort balance for allowance for doubtful accounts was \$1,063 as of September 30, 2020.
- (E) Represents taxes payable on gain, assumed 26% rate.
- (F) Represents full repayment of Allscripts Senior Secured Credit Facility upon transaction close.
- (G) Represents after tax gain, net of transaction fees and expenses, as if the transaction had occurred on September 30, 2020.
- (H) Represents elimination of Interest Expense related to the Allscripts Senior Secured Credit Facility, as if such debt was repaid on January 1, 2019 and 2020, respectively. The amounts are presented in the CarePort Historical column for illustrative purposes only and do not pertain to the CarePort Business.